MolDx Reimbursement Decision on Molecular Testing in Organ Transplants Causes Confusion, Concern

The billing article, issued in March by the MolDx test assessment program from Medicare contractor Palmetto, limits reimbursement to one test per patient encounter and provides new coding to define surveillance and for-cause testing. The article also stipulates coverage of surveillance testing only for patients who are enrolled in centers that use surveillance protocols and would otherwise receive such testing, and notes that Medicare will no longer reimburse for-cause tests unless used in place of a biopsy or to confirm biopsy results.

Source: https://www.genomeweb.com/molecular-diagnostics/moldx-reimbursement-decision-molecular-testing-organ-transplants-causes